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Structure of the Tie2 RTK Domain:
Self-Inhibition by the Nucleotide Binding
Loop, Activation Loop, and C-Terminal Tail
binding domain and an intracellular kinase domain. Binding of
extracellular ligand is believed to promote dimerization, which
leads to autophosphorylation and activation of the kinase do-
main [reviewed in 15]. Stringent regulation of the phosphoryla-
tion state and activity of the Tie2 kinase domain is crucial to
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Research Triangle Park, North Carolina 27709 normal vasculature development and maintenance. Tie2 activ-
ity is precisely regulated by the opposing actions of agonistic
and antagonistic extracellular ligands [16–18]. Tie2 activation
requires autophosporylation in response to binding its agonistsSummary
angiopoietin 1 (Ang1) and Ang4, whereas inactivation occurs
in response to Ang2 and Ang3. Tie2 mutations, which resultBackground: Angiogenesis, the formation of new vessels from
the existing vasculature, is a critical process during early devel- in ligand-independent and enhanced autophosphorylation,
cause hereditary venous malformations [19, 20]. Conversely,opment as well as in a number of disease processes. Tie2 (also
known as Tek) is an endothelium-specific receptor tyrosine transgenic mice that express a kinase-inactive form of Tie2 or
Tie2 null mice die in utero due to defects in their microvascula-kinase involved in both angiogenesis and vasculature mainte-
nance. ture [21, 22]. Inactivation of Ang1 or overexpression of Ang2
produces similar defects [17, 23, 24].
The broad clinical potential of antiangiogenic therapy is justResults: We have determined the crystal structure of the Tie2
kinase domain to 2.2 A˚ resolution. The structure contains the now being realized. Inhibition of either VEGFR2 or Tie2 by
small molecules, antibodies generated against the extracellularcatalytic core, the kinase insert domain (KID), and the C-termi-
nal tail. The overall fold is similar to that observed in other domain, and gene therapy have been shown to reduce tumor
progression [11, 25]. Therefore, the three-dimensional struc-serine/threonine and tyrosine kinase structures; however, sev-
eral unique features distinguish the Tie2 structure from those ture of the kinase domain of these receptors will enhance the
design of potent and selective small-molecule inhibitors asof other kinases. The Tie2 nucleotide binding loop is in an
inhibitory conformation, which is not seen in other kinase struc- therapeutic agents. To this end, we have determined the crystal
structure of the Tie2 kinase domain to a 2.2 A˚ resolution. Thetures, while its activation loop adopts an “activated-like” con-
formation in the absence of phosphorylation. Tyr-897, located structure contains the catalytic core, the kinase insert domain
(KID), and the C-terminal tail. Several unique features distin-in the N-terminal domain, may negatively regulate the activity
of Tie2 by preventing dimerization of the kinase domains or guish this structure from those of other receptor tyrosine ki-
nases whose structures are known [26–29]. Most notably, theby recruiting phosphatases when it is phosphorylated.
Tie2 nucleotide binding loop is in an inhibitory conformation,
which is not seen in other RTKs, while its activation loop adoptsConclusion: Regulation of the kinase activity of Tie2 is a com-
plex process. Conformational changes in the nucleotide bind- an “activated-like” conformation in the absence of phosphory-
lation.ing loop, activation loop, C helix, and the C-terminal tail are




The cytoplasmic kinase domain of Tie2 (Tie2K), residues 808–Vasculogenesis and angiogenesis are critical processes in
embryonic development as well as in a number of diseases, 1124, was expressed in baculovirus-infected insect cells. The
first 35 cytoplasmic residues (juxtamembrane) were not in-including ischemic coronary artery disease, cancer, diabetic
retinopathy, and rheumatoid arthritis [1–7]. While the precise cluded in the construct, and a 6-histidine tag was added at the
N terminus for purification purposes. Baculovirus-expressedmolecular mechanisms that regulate these processes have not
been fully elucidated, normal vascular development is known to Tie2K was heterogeneous with respect to phosphorylation.
Typically, preparations contained a mixture of proteins withbe dependent on the function of several endothelium-specific
receptor tyrosine kinases (RTKs) (reviewed in [8] and [9]). These 0–6 phosphoryl groups that could not be fully separated by
standard chromatographic procedures. Crystallization screensinclude the TIE RTKs, Tie1 and Tie2 (or Tek), as well as the
vascular endothelial growth factor receptor kinases (VEGFRs) were initially performed using a mixture of the non-, mono-,
and diphosphorylated species. Three different crystal forms of[1–4]. The VEGFRs are believed to play an early role in these
processes by directing the differentiation of mesodermal cells Tie2K were obtained; crystal forms I and II contained nonphos-
phorylated protein, while crystal form III contained monophos-into endothelial cells and the proliferation and migration of
endothelial cells to form primitive tubular vessels [10–12]. The phorylated protein (Table 1).
A mutant form of Tie2K provided a fourth crystal form. TwoTIE RTKs are involved in the later stages of modulating cell–cell
and cell–matrix interactions required for vascular remodeling major phosphorylation sites and one minor site were mapped
by mass spectrometry. The two major sites, Y897 and S1119,and maturation [13, 14].
Receptor tyrosine kinases comprise an extracellular ligand were mutated to phenylalanine and alanine, respectively, while
Key words: tyrosine kinase; Tek; angiogenesis; X-ray structure; kinase insert* To whom correspondence should be addressed (e-mail: lms18808@
glaxowellcome.com). domain; signal transduction
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Table 1. Crystal and Data Statistics
Crystal form I II III IV
Space Group P21 P212121 P212121 C2221
Unit cell a (A˚) 66 79 52 95
Unit cell b (A˚) 92 92 78 114
Unit cell c (A˚) 70 109 79 78
Unit cell b (8) 108 90 90 90
Mol/asu 2 2 1 1
Resolution (A˚) 2.2 2.5 2.2 2.1
Rsyma,b (%) 7.5 (20) 11 (29) 7.9 (23) 7.8 (25)
Completenessb (%) 96 (95) 98 (98) 99 (96) 98 (88)
Rcrystc (%) 19 21 20 21
Rfreed (%) 23 26 23 24
Number of nonhydrogen protein atoms 4766 4766 2368 2375
Number of solvent molecules 361 188 170 200
Rmsd from ideal
Bond lengths (A˚) 0.0058 0.0063 0.0064 0.0060
Bond angles (8) 1.15 1.16 1.19 1.15
a Rsym 5 ShkljI 2 ,I.jISI, where I is the observed intensity and ,I. is the average intensity from observations of symmetry-related reflections.
b Value in parentheses is for the highest resolution shell.
c Rcryst 5 ShkljjFobsj 2 jFcalcjj/SjFobsj, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively, for the hkl reflections.
d Rfree is calculated for a set of reflections that were not included in atomic refinement.
the minor site, Y1048, was mutated to phenylalanine. The mu- also contains functionally important loop regions: the glycine-
rich nucleotide binding loop (residues 831–836), the catalytictant form of Tie2K was purified to homogeneity as unphosphor-
ylated protein and gave rise to crystal form IV (Table 1). loop (residues 962–968), and the activation loop (residues 982–
1008), all of which will be described in further detail below.The structure of crystal form I was solved by molecular re-
placement using the structure of the unphosphorylated kinase
domain of fibroblast growth factor receptor 1 (FGFR1) [28] as Comparison to FGFR1
a search model. The structure was refined to an R factor of Of the reported kinase structures, the overall structure of Tie2K
19% at 2.2 A˚ resolution. Six residues at the N terminus, three most closely resembles the catalytic domain of FGFR1, with
residues at the C terminus, four residues in the activation loop,
and six residues connecting b3 and aC were disordered and
could not be modeled. The structures of crystal forms II, III, and
IV were solved by molecular replacement using the structure
determined for crystal form I. The Tie2K structure in all four
crystal forms was essentially identical, and this result suggests
that conformations observed in the structure are not due to
crystal packing forces. Residues disordered in crystal form I
were also disordered in crystal forms II, III, and IV. Superposi-
tion of all Cas yielded root mean square deviations (rmsd) of
0.18 A˚, 0.47 A˚, and 0.45 A˚ for I versus II, I versus III, and I
versus IV, respectively.
Overview of the Structure
The overall architecture of Tie2K was analogous to structures
reported previously for both serine/threonine and tyrosine pro-
tein kinases (reviewed in [30] and [31]). A Ca trace of Tie2K is
shown in Figure 1, where kinase secondary structural elements
are labeled according to the convention originally given for
cAPK [32]. Tie2K folds into two domains, with catalysis oc-
curring in a cleft between the two domains. Residues in the
N-terminal domain are primarily responsible for ligating ATP,
while residues in the C-terminal domain are involved in cataly-
sis and substrate binding.
The N-terminal domain (residues 808–904) folds into a
twisted b sheet and an a helix. The larger C-terminal domain
Figure 1. Overall Fold of Tie2K(residues 905–1124) contains seven a helices (aD–aI) and two
Ribbon diagram of the Tie2K structure. The a helices are blue, the b strandssets of anti-parallel b strands (b7/b8 and b9/b10). Strands 7
are red, the nucleotide binding loop is white, the catalytic loop is green, theand 8 are positioned at the interdomain interface adjacent to
activation loop is yellow, the KID is pink, and the C-terminal tail is orange.
the N-terminal b sheet. The kinase insert domain comprises The termini are denoted by N and C. Breaks in the chain occur between b3
two short helical segments that pack against the C-terminal and helix C and in the activation loop due to crystal disorder. The figure
was prepared with RIBBONS [45].lobe and the extended C-terminal tail. Like other kinases, Tie2K
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position. In Tie2K, b strands 3, 4, and 5 contain one additional
residue compared with FGFR1, and this extra residue produces
a change in the conformation of the loop regions connecting
these b sheets. That extension of the b3-b4-b5 sheet displaces
residues in the C helix by 2.5–5.5 A˚ from their equivalent posi-
tions in FGFR1. In addition, six Tie2K residues in the loop
connecting b3 with aC (A861–H866) are disordered in all four
crystal forms. Therefore, only three and a half turns of this helix
are observed for Tie2K as opposed to five for FGFR1.
In the N-terminal domain of kinases, two conserved, charged
residues form a salt bridge to correctly position the a- and
b-phosphates of ATP for catalysis. In Tie2K these residues
correspond to K855 on b3 and E872 on aC. Due to the shift
in aC, these residues are approximately 7.2 A˚ apart compared
with the approximately 3–4 A˚ distance observed in other kinase
structures [26–29]. While the shift in aC is not as dramatic as
observed in the structures of inactive cdk2 versus the activated
cdk2/cyclinA complex (8.5 A˚) [33], the conformational change
required to bring these residues into proper alignment for ATP
binding is not obvious.
The C-terminal lobes of Tie2K and FGFR1 are also quite
similar (Figure 2B) except for the positions of the activation
loops (see below) and the KID, which is disordered in FGFR1.
The C-terminal tail was included in our Tie2K construct but
not in FGFR1, IRK, or VEGFR2 and is observed in the crystal
structure presented here. This tail has an extended conforma-
tion that packs under the KID, runs along aI, F, and E, and
ends near the substrate binding site.
Activation Loop and Catalytic Residues
Protein kinases contain a large flexible loop, called the activa-
tion loop or A-loop, whose conformation is believed to regulate
kinase activity. In many kinases, the conformation of the A-loop
is controlled by the phosphorylation of specific residues within
this region [30]. The activation loop generally begins with a
conserved Asp-Phe-Gly sequence (Tie2K 982–984) and ends
at a conserved Ala-Pro-Glu (Tie2K 1006–1008) [30]. In struc-
Figure 2. Superposition of the N- and C-Terminal Domains of Tie2K and tures of inactive kinases, this loop often blocks either the
FGFR1 substrate or the ATP binding sites [26, 28, 29]. Upon phosphor-
(A) Ribbon diagram of the N-terminal domains of Tie2K and FGFR1 in which ylation, the A-loop is repositioned to contact residues in the
the Cas of the b sheets have been superimposed. Tie2K is shown in red, C-terminal domain [27]. The activating phosphate can then
and FGFR1 is shown in blue. The dashed line indicates the position of the interact with a cluster of basic residues that include a con-
disordered loop connecting b3 and helix C in Tie2K.
served arginine (Tie2K R963) that precedes the catalytic aspar-(B) Ribbon diagram of the C-terminal domains of Tie2K and FGFR1 in which
ate (Tie2K D964). The aspartyl residue of the Asp-Phe-Gly motifthe Cas of the a helices have been superimposed. Tie2K is shown in red,
ligates a Mg21 ion, which in turn contacts the b- and g-phos-and FGFR1 is shown in blue. The activation loops for Tie2K and FGFR1 are
shown in yellow and white, respectively. The C-terminal tail and KID for phates of ATP.
Tie2K are shown in green. Figures were prepared with QUANTA [43]. In Tie2K the activation loop corresponds to residues 982–
1008 and contains a single tyrosine at position 992. The con-
served Ala-Pro-Glu sequence is Ala-Ile-Glu in Tie2. In the Tie2K
structure presented here, the A-loop more closely resembleswhich it shares approximately 45% sequence identity [28].
Superposition of the five b strands in the N-terminal domains that of activated IRK than that seen for inactive, unphosphory-
lated FGFR1 (Figure 3). Four residues (T996–R999) near theof Tie2K and FGFR1 yielded an N-terminal domain Ca rmsd of
0.76 A˚; superposition of the C-terminal domains using Cas from C-terminal end of Tie2K’s A-loop are disordered. All attempts
to autophosphorylate Y992 in the activation loop using purifiedthe seven a helices gave a C-terminal domain Ca rmsd of
0.58 A˚. Like unphosphorylated FGFR1, Tie2K is in an opened wild-type protein have been unsuccessful. However, when ty-
rosines 897 and 1048 and serine 1119 were mutated to phenyl-conformation with a relative rotation of approximately 158
between the N- and C-terminal lobes when compared to alanine and alanine, respectively, the purified protein could be
quantitatively phosphorylated on Y992. These observationsthe closed, active structure of the insulin receptor kinase
(IRK) [27]. suggest that the mode by which Tie2 is activated is complex
and may differ from that found with other RTKs [30].The b sheet topologies in the N-terminal domain of FGFR1
and Tie2K are quite similar (Figure 2A). However, significant The conformation of the conserved Asp-Phe-Gly motif of the
activation loop is also significantly different than that seen indifferences are observed in the nucleotide binding loop, the
loops connecting b3 to aC and b4 to b5, and the C helix other kinase structures [26–29]. The side chains of D982 and
Structure
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Figure 3. Activation, Nucleotide Binding, and Catalytic Loops in Tie2K, Unphosphorylated FGFR1, and Activated IRK
The nucleotide binding loop and helix C are shown in green, the activation loop is shown in red, and the catalytic segment is shown in blue. The lysine and
glutamic acid residues that form a salt bridge are shown in yellow. The aspartate and arginine of the catalytic HDRLAAR motif are shown in blue, while the
aspartate and phenylalanine of the Asp-Phe-Gly motif at the beginning of the activation loop are shown in pink. Loops disordered in the crystal structures
are indicated by dashed lines. The figures were generated using QUANTA.
F983 point in directions opposite to those observed in non- aspartate binds Mg21 and the g-phosphate of ATP. The confor-
mation of the nucleotide binding loop is further stabilized byphosphorylated FGFR1 and activated IRK (Figure 3). The D982
side chain is directed toward the back of the pocket and away hydrogen bonds between the backbone carbonyl of F835 and
the NZ of K855, the backbone NH of N834 and OD1 of N969,from the ATP binding site. The Tie2K side chain of F983 extends
toward the solvent and is sandwiched between the side chains and OD1 of N834 and the backbone NH of F983.
The unusual conformation of the nucleotide binding loop inof K855 of b3 and E872 of aC, the conserved residues that form
the salt bridge required to correctly position the phosphates of Tie2K cannot readily be explained on the basis of primary
sequence. Sequence comparisons between Tie2K and otherATP. Although the Tie2K activation loop adopts an “active-like”
conformation overall, the Asp-Phe-Gly motif at the beginning of serine/threonine and tyrosine kinases do not reveal any unique
residues in Tie2K.this loop has a conformation that could inhibit ATP binding.
The catalytic loop of protein kinases lies between aE and ATP was modeled into the active site of Tie2K based on the
structure of activated IRK. As seen in Figure 4, the nucleotideb7 and contains an invariant aspartic acid (D964 in Tie2) that
serves as the catalytic base in the phosphotransfer reaction binding loop precludes binding of ATP. In agreement with and
predicted by the Tie2K structure, we have not been successful[30]. The catalytic loops of Tie2, FGFR1, VEGFR2, and IRK are
identical in sequence: His-Arg-Asp-Leu-Ala-Ala-Arg-Asn [26, in soaking ATP into existing crystals or cocrystallizing this
kinase with ATP.28, 29]. In Tie2K, the backbone and side chain positions of this
loop are similar to those in the unliganded FGFR1 and VEGFR2
and in the ternary phosphorylated IRK complex structures (Fig- Kinase Insert Domain
Many RTKs contain an insert of variable length and sequenceure 3).
between aD and aE in their C-terminal domain. This insert can
be as short as 12 or as long as 97 residues, as in IRK and theNucleotide Binding Loop
The nucleotide binding loop contains residues responsible for platelet-derived growth factor receptor b (PDGFRb), respec-
tively [26, 34]. Deletion or mutation of this region in other ki-binding the triphosphate moeity of ATP in the correct position
for catalysis [30]. This glycine-rich loop is believed to be quite nases revealed that the KID is not necessary for intrinsic kinase
activity [29, 34, 35]. However, this KID may be important forflexible and is often either disordered or has high B factors in
many unliganded kinase structures [28, 29]. protein–protein interactions involved in signal transduction via
autophosphorylation of KID tyrosine residues [34, 35]. In Tie2,In Tie2K, this loop adopts a unique self-inhibitory conforma-
tion with residues 832–836 occupying the ATP binding site this region corresponds to residues 916–936 and does not
contain tyrosine residues. Its function, if any, is not known.(Figure 4). The g carboxylate of E832, if protonated, could form
a hydrogen bond with the backbone carbonyl of E903. The Due to the lack of sequence conservation in this domain,
structural conservation is also not expected. In FGFR1, thebackbone carbonyl of E903 presumably participates in the
binding of ATP through a hydrogen bond to the 6 amino group KID is apparently quite mobile and disordered in the crystal
structure of the unliganded protein [28]. In VEGFR2, the KIDof the nucleotide. The a- and b-phosphate binding sites of ATP
are occupied by N834 and G836. F835 sits in a pocket at the was deleted in the construct used for structural studies [29].
In the IRK structure, this region, P1093-G1100, is proline richback of the site formed by the side chains of K855, I886, I902,
and F983. N834 occupies the site of the conserved aspartate and forms a loop that folds toward the N-terminal domain
[26]. In Tie2K, the KID consists of two short helical segmentsof the Asp-Phe-Gly motif located in the A-loop. This conserved
Structure of the Tie2 RTK Domain
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Figure 5. Kinase Insert Domain and C-Terminal Tail
Ribbon diagram of the KIDs of Tie2K and IRK in which the Cas of the
C-terminal domain a helices have been superimposed. Tie2K is shown in
red, and IRK is shown in green. The KID and C-terminal tail for Tie2K is
shown in yellow. The KID for IRK is shown in blue. Y1101 and Y1112 are
highlighted in purple. Figures were prepared with QUANTA.
Grb7, Grb14, Shp2, the p85 subunit of PI3 kinase, and the PTB
domain of Dok-R [36–40].
In our unliganded crystal structure, the hydroxyls of Y1101
and Y1112 are not solvent exposed and appear to play a struc-
tural role (Figure 5). The hydroxyl of Y1101 hydrogen bonds to
the side chain of E759, while the phenyl ring is packed between
the side chains of M757 and K762. The hydroxyl of Y1112
hydrogen bonds to the main chain NH and carbonyl oxygen
of L579 and A592, respectively. The phenyl ring of Y1112 sits
in a hydrophobic pocket formed by the side chains of L696,
L579, F1114, and R577. Mass spectrometric analysis of the
baculovirus-expressed Tie2K found that Y897 and Y1048,
which point directly out into solvent, are partially phosphory-
lated. There was no evidence for phosphorylation of Y1101 or
Y1112.Figure 4. ATP Binding Site
In the unphosphorylated FGFR1 and IRK structures, the acti-(A) Superposition of the N-terminal b sheets of Tie2K and activated IRK Cas
vation loop blocks access to the substrate binding site [26,of b1–b5 were used to superimpose the structures of Tie2K and activated
IRK (PDB entry 1IR3). Tie2K is shown in red, IRK is shown in green, and 28]. In Tie2K, the activation loop adopts an “active-like” confor-
ATP from the IRK structure is shown in yellow. The figure was prepared mation, while the end of the C-terminal tail could block access
with QUANTA. to the substrate binding site. In the structure presented here,
(B) Surface representation of the ATP binding site of Tie2K. The nucleotide
the last three residues of the C-terminal tail are disordered.binding loop is shown as a purple stick figure. The position of ATP, based
The last ordered residue of the C-terminal tail, E1120, forms aon the superposition in Figure 5A, is shown in yellow. The figure was pre-
salt bridge with R915 and is positioned near the peptide bindingpared with GRASP [46].
site in the activated IRK-peptide complex (Figure 6). Therefore,
these data suggest that with the Tie2K construct used in these
structural studies, the C-terminal tail must undergo a confor-connected by a turn, as shown in Figure 5, and packs against
mational change upon activation of the protein and exposeresidues 1104–1112 in the C-terminal tail.
both the substrate binding site and Y1101 and Y1112 for phos-
phorylation and signaling.
C-Terminal Tail: Interaction with Accessory Proteins
The C-terminal tail of Tie2 has been shown to bind a number of Mutational Analysis – Vascular Dysmorphogenesis
Two mutations in the N-terminal domain of Tie2, R849W andproteins containing src homology 2 (SH2) and phosphotyrosine
binding (PTB) domains in a phosphotyrosine-dependent man- Y897S, segregate with an autosomal dominant condition re-
ferred to as vascular dysmorphogenesis [19, 20]. This conditionner. Numerous reports suggest that tyrosines 1101 and 1112
in the C-terminal tail interact with the SH2 domains of Grb2, is characterized by lesions consisting of haphazardly arranged,
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Figure 6. Proximity of the C-Terminal Tail to the Substrate Binding Site
Solvent-exposed surface representation of the Tie2K active site is shown
in white. The surface of the C-terminal tail is shown in blue. ATP and peptide
substrate from the activated IRK complex structure are modeled into the
Tie2K active site by superimposing the Cas of the C-terminal domain a
helices. The surface of the peptide substrate is highlighted in red; ATP is
shown in yellow. The figure was prepared with QUANTA.
dilated blood vessels that lack or have a reduced smooth-
muscle layer and little to no supportive tissue. Receptor tyro-
sine kinases require the binding of an extracellular ligand to
promote dimerization, autophosphorylation, and activation of
the kinase domain (reviewed in [15]). These two mutations
result in ligand-independent autophosphorylation and activa-
tion of Tie2 [19, 20]. Tie2 is able to autophosphorylate to its fully
Figure 7. Noncrystallographic Dimeractive state without ligand-mediated receptor dimerization. It
The backbones of the two molecules in the asymetric unit are shown in redhas been suggested that these mutations either promote di-
and green. The activation loops for molecules 1 and 2 are shown in yellowmerization of the protein in the absence of an extracellular
and blue. The nucleotide binding loops for both molecules are shown in
ligand or relieve autoinhibition of the kinase [19]. We have white. The figure was prepared with QUANTA.
examined the structure of Tie2K in its unphosphorylated and
monophosphorylated (Y897) states, as well as the activity of
the wild-type and the Y897F/Y1048F/S119A mutant proteins, face. Y897, Y899, R849, and D828 are located at the edges of
the interface. R849, the first residue of b3, makes a weakand we speculate on how the R849W and Y897S mutations
might activate Tie2K activity. hydrogen bond to Q837 of the neighboring molecule. The side
chain of R849 is packed between the side chains of Y897 andPurified wild-type Tie2K, a significant fraction of which is
phosphorylated on Y897, has a very low level of kinase activity V829 from the neighboring molecule. Y897 is located on the
loop connecting b4 and b5 and packs against R849. Mutationand could not appreciably autophosphorylate Y992 in the acti-
vation loop. The Y897F/Y1048F/S119A mutant, on the other of R849 to tryptophan may allow for better packing at this
predominantly hydrophobic interface. On the other hand, phos-hand, could autophosphorylate Y992, and this ability led to an
approximately 100-fold increase in kinase activity. Therefore, phorylation of Y897 would be difficult to accommodate at this
tight crystal contact and would therefore lead to crystal formwhile the nonphosphorylated and monophosphorylated wild-
type proteins and the Y897F/Y1048F/S119A mutant protein III. If this crystal contact is in fact a biologically significant
dimer interface, the phosphorylation state of Y897 may behave identical crystal structures, Y897 influences the activity
of the protein in solution. another mechanism of controlling the activity of Tie2. When
Y897 is phosphorylated, the cytoplasmic kinase domains can-Tie2K crystal forms I and II, which contain unphosphorylated
protein, have two molecules in the asymmetric unit. The crystal not dimerize. However, when Y897 is unphosphorylated or
mutated to a serine, Tie2K dimerization is favored.form III, which contains monophosphorylated protein (Y897),
contains only one molecule in the asymmetric unit. In the two Alternatively, R849 and Y897 could influence Tie2 activity in
vivo by interacting with accessory proteins. Phosphorylatedunphosphorylated crystal forms, one crystal contact (approxi-
mately 1096 A˚2) is conserved at the noncrystallographic 2-fold Y897 has been shown to bind the SH2 domain of the protein
tyrosine phosphatase Shp2 [36, 39]. This interaction may allowaxis (Figure 7). This contact primarily involves b1 but also
residues from the ends of b2, b3, and b4 in the N-terminal the phosphatase to dephosphorylate Y992 in the activation
loop and therefore to downregulate the activity of the kinase.domain. Residues R849 and Y897 sit at this crystal contact.
F826, V829, and L839 form the hydrophobic core of this inter- The R849W and Y897S mutations may disrupt the recognition
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fluorescent energy transfer from Eu to APC. The plate was read on a Victorsite for Shp2 or the kinase that phosphorylates Y897. Clearly,
in time resolved–fluorescence mode by exciting at 340 nm and reading themore experiments will be required to understand these muta-
emission at 665 nm.tions and the role of Y897 in kinase inhibition and/or activation.
Protein Digestion for Mass SpectrometryBiological Implications
Trypsin digestions of 200–1000 pmol of Tie2K were carried out in 50 mM
Tris [pH 8.5], 1 mM CaCl2, and 10% acetonitrile. In some instances, Tie2K
The crystal structure of unliganded Tie2K has revealed the was reduced and alkylated with DTT and 4-vinylpyridine prior to digestion.
structure of the kinase insert domain as well as several novel Digestion proceeded at 378C for 12–18 hr.
modes of self-inhibition. The position of the nucleotide binding
loop and the Asp-Phe-Gly motif of the activation loop preclude Mass Spectrometry: LCMS
Mass measurements of intact protein were determined by using liquid chro-ATP binding, while the C-terminal tail could block substrate
matography mass spectrometry (LCMS). Protein samples were initially de-binding. Phosphorylation of the N-terminal domain may serve
salted on a Poros R2/H column (Perceptive Biosystems; Framingham, MA).as a negative regulatory mechanism by either preventing di-
Effluent from the desalting column was directed to a SCIEX API III massmerization and autophosphorylation of the intracellular cata- spectrometer (PE Sciex, Concord, ON, Canada), and spectra were acquired
lytic domains or recruiting a phosphatase. While the mecha- in positive-ion mode with electrospray ionization. Intact protein mass values
nisms by which Tie2 is activated for catalysis remain unclear, were obtained from the reconstructed mass spectra that were generated
from the processed data. Assignment of phosphorylation states was madeconformational changes in the nucleotide binding loop, the
by identifying masses that were multiples of 80 Da higher than the expectedactivation loops, the C-terminal tail, and C helix will all be
mass of Tie2K.required for both ATP and substrate binding. We are currently
trying to crystallize Tie2K mutants in their activated form in
Mass Spectrometry: NanoES MSorder to understand the regulatory mechanisms of this kinase.
Nanoelectrospray ionization (nanoES) MS on a Q-TOF instrument from Mi-
cromass (UK) was used to map phosphorylation sites after trypsin digestion.Experimental Procedures
Sample was introduced to the MS with either static nanoES using a pulled
capillary tip (Mann) or capillary LCMS/MS. The LC system was from LCProtein Expression
Packings and consisted of the Famos autosampler and the Ultimate solventThe cytoplasmic domain of Tie2 was cloned from a human kidney cDNA
delivery pump. Separation was carried out on a 75 mm I.D. C18 PepMaplibrary (Clontech, Palo Alto, CA) by PCR. The sequence was identical to that
column, also from LC Packings. The Q-TOF is capable of data dependentreported in GenBank (L06139). The coding region corresponding to residues
ion selection for collision-induced fragmentation.808–1124 was subcloned into a pFASTBAC1 (GIBCO-BRL) expression vec-
Two sample preparation approaches were used to map the phosphoryla-tor by PCR. The N-terminal primer included an Sst1 restriction site and a
tion sites. In the first approach, phosphorylated peptides were isolatedmethionine start codon followed by six histidine codons. The C-terminal
from nonphosphorylated peptides by using Ga(III) immobilized metal affinityprimer included a stop codon and an Xho1 restriction site. The PCR product
chromatography (IMAC). Briefly, an aliquot of the trypsin digest was acidifiedwas cloned into the Sst1/XhoI site of pFASTBAC1. The Tie2K construct
and loaded onto an IMAC microcolumn charged with Ga(III). The columnwas transfected into Spodoptera frugiperda (Sf9) cells, single plaques were
was then washed with 0.1% acetic acid/ 30% acetonitrile to remove non-isolated, and high-titer stocks were generated. Sf9 cells were infected at a
phosphorylated peptides. Retained peptides were then eluted with 0.2 Mmultiplicity of infection of 5 for 72 hr and harvested by centrifugation.
sodium phosphate (pH 8.2) and directly applied to a microcolumn packed
with Poros R2/H reverse-phase media. Bound peptides were washed withProtein Purification
0.1% formic acid and then eluted directly into a nanoelectrospray capillaryCells were resuspended in 50 mM HEPES (pH 8), 200 mM NaCl, and 20 mM
tip. Static nanoESI was used to acquire MS and MS/MS spectra of theimidazole and were disrupted by a polytron homogenizer and sonication.
purified peptides. Phosphorylated residues were identified from MS/MSThe homogenate was centrifuged for 40 min at 12,500 rpm. The supernatant
data.was filtered (1.2 micron cartridge filter) and was loaded onto a Ni-chelating
In the second approach, the Tie2K trypsin digest was analyzed by capillarycolumn (Pharmacia Chelating Sepharose FF). Protein was eluted with a 10
LCMS/MS with data-dependant scanning. This data file was then used tocolumn volume linear gradient between 20 and 300 mM imidazole in 50 mM
conduct a Mascot protein database search that compares uninterpretedHEPES (pH 8) and 200 mM NaCl. Tie2K protein was pooled and loaded
MS/MS data to theoretical MS/MS spectra of user-specified proteolyticdirectly onto a hydroxylapatite column (BioRad Type I ceramic hydroxylapa-
peptides. The spectra were interpreted manually to confirm the assignment.tite). A linear gradient was run from 0 to 100 mM potassium phosphate in
20 mM Tris-HCl (pH 8), 50 mM NaCl, 5 mM DTT, and 5% glycerol. The Tie2K-
containing fractions were diluted 1:1 with 20 mM Tris-HCl (pH 8), 5 mM Crystallization and Data Collection
DTT, and 5% glycerol, loaded onto an anion exchange column (Pharmacia All four crystal forms of Tie2K were grown by the hanging-drop vapor diffu-
Q-Sepharose HP), and eluted with a 0–600 mM NaCl gradient. Tie2K was sion method. The protein (6 mg/ml in 20 mM HEPES [pH 7.5], 300 mM NaCl,
pooled based upon SDS-PAGE analysis (.95% purity) and stored at –808C. 5 mM DTT) was mixed with an equal volume of reservoir and incubated at
228C. The reservoir for crystal forms I and II was 2.5% PEG12000, 2.5%
In Vitro Autophosphorylation for Mass Spectrometry glycerol, 100 mM HEPES (pH 7.5), and 10 mM spermidine. The reservoir for
Wild-type and mutant Tie2K were incubated with 2 mM ATP and 10 mM crystal form III was 100 mM HEPES (pH 7.5), 100 mM KCl, and 10% isopropa-
MgCl2 for 30 min at room temperature in 25 mM HEPES (pH 7.5), 150 mM nol, while the reservoir for crystal form IV was 100 mM HEPES (pH 7.5) and
NaCl, and 10 mM DTT. Samples were flash frozen and stored at 21808C 1.5 M NaCl. Crystals belonging to the four different space groups appeared
until they could be analyzed by mass spectrometry. within several days to several weeks and typically grew to approximately
100 3 100 3 10 mm in 1–2 months. Glycerol was added to a final concentration
of 25% as a cryoprotectant, and the crystals were flash frozen in liquid N2.In Vitro Kinase Assay
Nonactivated or preactivated Tie2K (10 nM) was used to phosphorylate 1 Data for crystal forms I, II, and IV were collected at beamline 17-ID on a
MAR-CCD in the facilities of the Industrial Macromolecular CrystallographymM peptide substrate (Biotin-Ahx-LEARLVAYEGWVAGKKK-NH2; Synpep,
Dublin, CA) in the presence of 80 mM ATP, 10 mM MgCl2, 1 mM DTT, 0.1 Association Collaborative Access Team (IMCA-CAT) at the Advanced Pho-
ton Source. These facilities are supported by the companies of the Industrialmg/ml BSA, and 0.1 M HEPES (pH 7.5). The reaction was carried out at
room temperature for 30 min and then stopped by the addition of 50 mM Macromolecular Crystallography Association through a contract with Illinois
Institute of Technology (IIT). This contract is executed through IIT’s CenterEDTA. Streptavidin-APC (1.2 mg/ml) (Molecular Probes, Eugene, OR) and
0.15 mg/ml Eu-a-pY (EG&G Wallac, Gaithersburg, MD) in the presence of for Synchrotron Radiation Research and Instrumentation. The data were
processed using HKL2000 [41]. Data for crystal form III was collected on0.1 mg/ml BSA and 0.1 M HEPES [pH7.5] were added, and the reactions
were incubated for 10 min at room temperature. Streptavidin-APC and Eu- an RAXIS4 image plate operating on a Rigaku rotating anode generator.
The data were processed with DENZO and scaled with SCALEPACK [41].a-pY bind to the phosphorylated peptides to form a complex, allowing
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Structure Determination and Refinement duction and signal diversity by receptor oligomerization. Trends Bio-
chem. Sci 19, 459–463.The structure of crystal form I was solved first and was subsequently used
to solve the other three crystal forms. The structure was solved by molecular 16. Davis, S., et al., and Yancopoulos, G.D. (1996). Isolation of angiopoietin-1,
a ligand for the TIE2 receptor, by secretion-trap expression cloning.replacement using CNS [42] and FGFR1 as a search model (molecule 1 of
PDB entry 1FGK) [28]. The search model contained FGFR1 residues 464–485, Cell 87, 1161–1169.
17. Maisonpierre, P.C., et al., and Yancopoulos, G.D. (1997). Angiopoietin-2,491–500, 506–578, 592–647 and 651–761. Residues not conserved between
FGFR1 and Tie2 were truncated to alanine in the model. The correct solutions a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science
277, 55–60.were the top two peaks in both the rotation and translation functions and
had correlation coefficients of 0.38 and 0.36. Rigidbody refinement gave an 18. Valenzuela, D.M., et al., and Yancopoulos, G.D. (1999). Angiopoietins 3
and 4: diverging gene counterparts in mice and humans. Proc. Natl.R factor of 49%. Multiple rounds of model building and refinement were
carried out with QUANTA [43] and CNS. The overall structure was confirmed Acad. Sci. USA 96, 1904–1909.
19. Vikkula, M., et al., and Olsen, B.R. (1996). Vascular Dysmorphogenesisby a composite omit map calculated with CNS. Residues 813, 858, 860,
867, 997, 1099, and 1119 were modeled as alanine in all four crystal forms caused by an activating mutation in the receptor tyrosine kinase Tie2.
Cell 87, 1181–1190.due to a lack of side chain density. Structure analysis with PROCHECK
indicated that all main chain torsions fall within the allowed regions of the 20. Calvert, J.T., et al., and Marchuk, D.A. (1999). Allelic and locus heteroge-
neity in inherited venous malformations. Hum. Mol. Genet. 8, 1279–1289.Ramachandran plot [44].
21. Sato, T.N., et al., and Qin, Y. (1995). Distinct roles of the receptor tyrosine
kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74.Acknowledgments
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